Nature Communications 6, Article number: 6072 (2015); Published 23 January 2015; Updated 8 July 2015
In the Discussion section of this Article, we inadvertently stated that ‘endogenous IL-27 signalling results in reduced tumour burden’. This should have read: ‘lack of IL-27 signalling results in reduced tumour burden’.
Additional information
The online version of the original article can be found at 10.1038/ncomms7072
Rights and permissions
About this article
Cite this article
Zhu, C., Sakuishi, K., Xiao, S. et al. Correction: Corrigendum: An IL-27/NFIL3 signalling axis drives Tim-3 and IL–10 expression and T-cell dysfunction. Nat Commun 6, 7657 (2015). https://doi.org/10.1038/ncomms8657
Published:
DOI: https://doi.org/10.1038/ncomms8657
This article is cited by
-
Alternative Checkpoints as Targets for Immunotherapy
Current Oncology Reports (2020)
-
IL-27, but not IL-35, inhibits neuroinflammation through modulating GM-CSF expression
Scientific Reports (2017)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
